OR 449
Alternative Names: OR-449Latest Information Update: 19 Jan 2023
Price :
$50 *
At a glance
- Originator Orphagen Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Steroidogenic factor 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adrenocortical carcinoma
Most Recent Events
- 17 Jan 2023 OR 449 receives Rare Pediatric Disease Designation for Adrenocortical carcinoma in USA
- 11 Jun 2022 Pharmacodynamics data from a preclinical study in Adrenocortical carcinoma(ACC) presented at the 104th Annual Meeting of the Endocrine Society (ENDO-2022)
- 11 Jun 2022 Pharmacodynamics data from a preclinical study in Adrenocortical cancer presented at the 104th Annual Meeting of the Endocrine Society (ENDO-2022)